Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Subscribe To Our Newsletter & Stay Updated
